What is Leerink Partnrs' Forecast for GPCR FY2024 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Equities researchers at Leerink Partnrs cut their FY2024 earnings per share estimates for Structure Therapeutics in a research note issued to investors on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of ($0.76) for the year, down from their previous estimate of ($0.59). The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.80) per share. Leerink Partnrs also issued estimates for Structure Therapeutics' Q4 2024 earnings at ($0.20) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.85) EPS and FY2028 earnings at ($0.86) EPS.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. HC Wainwright initiated coverage on Structure Therapeutics in a report on Wednesday. They set a "buy" rating and a $80.00 target price for the company. JMP Securities dropped their target price on Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a research report on Friday, August 9th. Finally, Morgan Stanley started coverage on Structure Therapeutics in a research report on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $85.67.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded up $2.11 during midday trading on Friday, hitting $33.35. 826,642 shares of the company's stock were exchanged, compared to its average volume of 785,200. The company has a market cap of $1.91 billion, a PE ratio of -44.50 and a beta of -3.41. The firm has a 50-day moving average of $37.46 and a two-hundred day moving average of $39.32. Structure Therapeutics has a 12 month low of $26.61 and a 12 month high of $62.85.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in Structure Therapeutics by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company's stock worth $341,015,000 after acquiring an additional 221,851 shares during the period. FMR LLC lifted its holdings in shares of Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company's stock worth $268,977,000 after purchasing an additional 383,635 shares during the period. Janus Henderson Group PLC boosted its position in Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock valued at $173,623,000 after buying an additional 602,609 shares during the last quarter. Driehaus Capital Management LLC increased its holdings in Structure Therapeutics by 3.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company's stock worth $101,204,000 after buying an additional 86,833 shares during the period. Finally, Federated Hermes Inc. raised its position in Structure Therapeutics by 6.6% during the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company's stock worth $94,531,000 after buying an additional 150,000 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.